A shot every six months, Gilead Sciences' new HIV prevention drug has received FDA approval. The HIV-1 capsid inhibitor Yeztugo (lenacapavir) becomes the first and only HIV prevention regimen that requires dosing only twice a year. Based on phase 3 study data, over 99.9% of participants maintained HIV-negative status after dosing twice a year. This should be considered a significant breakthrough in the fight against HIV. Shouldn't the $GILD stock price multiply a few times? It's worth paying attention to.